Singapore to begin coronavirus vaccine human trials this week – Livemint

0
85
Singapore to begin coronavirus vaccine human trials this week – Livemint


In this handout photo released by the University of Oxford samples from coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England Thursday June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday July 20, 2020 in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP) (AP)
In this handout photo released by the University of Oxford samples from coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England Thursday June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday July 20, 2020 in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP)(AP)

1 min read

.Updated: 27 Jul 2020, 07:38 AM IST



Bloomberg

  • ‘Lunar-Cov19’ is among 25 vaccine candidates globally to reach human-trials stage and will be tested on 108 healthy volunteers of various ages in Singapore
  • The trial will determine the vaccine’s safety

Singapore will start human trials as early as this week for a Covid-19 vaccine being developed by Duke-NUS Medical School and American pharmaceutical company Arcturus Therapeutics, the Straits Times reports.

‘Lunar-Cov19’ is among 25 vaccine candidates globally to reach human-trials stage and will be tested on 108 healthy volunteers of various ages in Singapore, the newspaper said.

The trial will determine the vaccine’s safety and its ability to produce the “soldiers” needed to help the body fight an infection, Professor Ooi Eng Eong, deputy director of Duke-NUS Medical School’s emerging infectious diseases programme, was cited as saying.

Subscribe tonewsletters

*Enter a valid email

*Thank you for subscribing to our newsletter.

Click hereto read the Mint ePaperLivemint.com is now on Telegram.Join Livemint channelin your Telegram and stay updated

Close

No Network

Server Issue

Internet Not Available

×

Real More »